Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Surveillance of ReFacto AF in Hemophilia A
NCT00884390Phase 4Terminated
- Sponsor
- Pfizer
- Start
- May 2009
- Primary completion
- Mar 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 14
01
Overview
Phase 4, open-label, single-arm trial of moroctocog alfa in hemophilia A, sponsored by Pfizer. Primary endpoint: Number of Participants With Clinically Significant Factor VIII Inhibitor Development. Started May 2009; status: terminated.
02
Drugs
moroctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT00884390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00884390.